Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;4(2):125-30.
doi: 10.1097/COH.0b013e3283223d61.

How HIV changes its tropism: evolution and adaptation?

Donald E Mosier  1
Affiliations
Review

How HIV changes its tropism: evolution and adaptation?

Donald E Mosier. Curr Opin HIV AIDS. 2009 Mar.

Abstract

Purpose of review: To present recent information on the evolution of coreceptor use from CCR5 alone to CCR5 and CXCR4, the impact CCR5 inhibitors have on this process, and new insights into HIV-1 binding to CD4 and CCR5.

Recent findings: The findings that are summarized include resistance to CCR5 inhibitors, genotypic predictors of coreceptor use, the link between coreceptor use and cell tropism, and new data on CCR5 structure and function.

Summary: Resistance to CCR5 inhibitors is uncommon, and frequently involves selection of minor populations of R5X4 virus. Genotypic predictors of coreceptor use need to take into account the entire envelope sequence, not just V3. Genetic polymorphisms in humans that affect CCR5 or chemokines that bind CCR5 affect not only virus entry but also immune reconstitution.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution of coreceptor use gr1 Schematic depiction of CCR5 and CXCR4 use during the course of HIV-1 subtype B infection. Yr PI, years postinfection; percentage max CoR use, percentage of maximal entry via CCR5 or CXCR4 during the course of infection; dual-R, R5X4 viruses with better entry via CCR5; dual-X, R5X4 viruses with better entry via CXCR4.
See this image and copyright information in PMC

References

    1. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol. 2005;13:269–277. - PubMed
    1. Peters PJ, Duenas-Decamp MJ, Sullivan WM. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008;5:5. - PMC - PubMed
    1. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16:339–354. - PubMed
    1. Whitcomb JM, Huang W, Fransen S. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566–575. - PMC - PubMed
    1. Huang Y, Paxton WA, Wolinsky SM. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–1243. - PubMed

Publication types